Virtual Library
Start Your Search
M. Grivaux
Author of
-
+
P1.07 - Poster Session/ Small Cell Lung Cancer (ID 221)
- Event: WCLC 2015
- Type: Poster
- Track: Small Cell Lung Cancer
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.07-013 - Real-Life 2-Year Therapeutic Strategies in the Management of 525 Small-Cell Lung Cancers: The ESCAP Study Preliminary Results (ID 1657)
09:30 - 09:30 | Author(s): M. Grivaux
- Abstract
Background:
In the last years, new drugs and strategies have emerged in the management of lung cancer (LC). The French College of General Hospital Respiratory Physicians therefore promoted a prospective multicenter epidemiological study: the ESCAP study. This study was aimed to describe the therapeutic strategies implemented during the first 2-year after diagnosis in patients with LC followed in French General Hospital chest departments. We report below descriptive results for small-cell lung cancer (SCLC).
Methods:
For each patient with a LC diagnosed in 2010, a standardized form was completed at diagnosis and following each change in treatment strategy up to at least 2 years after diagnosis.
Results:
53 centers participated in the ESCAP study, and included 3,943 LC patients. Of these, 525 patients had a SCLC. Characteristics of SCLC patients at diagnosis were: mean age +/- standard deviation (SD), 65.6 +/- 10.8 years; male, 77%; never-smokers, 4.8%. The mean follow-up in SCLC patients was 10.5 months (SD: 8.8) and median number of strategies was 2 (Interquartile range: 1-3). Main strategy characteristics are summarized in the following table.
As regards first strategy, cisplatin (46%) and carboplatin (42%) were the most frequent used drugs associated with etoposide. As regards second strategy, the most frequently used drugs were topotecan (22%), etoposide (21%), or carboplatin (20%). Few patients received targeted therapy (< 1% in strategies 1 and 2).First strategy (N=525) Second strategy (N=309) Third strategy (N=153) Duration (months): mean+/-SD 5.4 +/- 4.5 3.6 +/- 3.5 2.7 +/- 2.4 Curative surgery 2% 1% - Radiotherapy 10% 47% 20% Radiochemotherapy 15% - - Chemotherapy 75% 55% 61% Exclusive supportive care 8% 14% 27% Patients died during the strategy 195 (37%) 134 (43%) 90 (59%) Patients with a new strategy 309 (59%) 153 (50%) 54 (35%)
Conclusion:
The ESCAP study describes the 2-year management of SCLC on real-life settings in France. Its preliminary results showed that 3 or 4 strategies were not uncommon in the management of SCLC patients.
-
+
P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.01-048 - Real-Life 2-Year Therapeutic Strategies in the Management of Metastatic Non-Small-Cell Lung Cancers: The ESCAP Study (ID 1515)
09:30 - 09:30 | Author(s): M. Grivaux
- Abstract
Background:
In the last years, new drugs and strategies have emerged in the management of lung cancer (LC). The French College of General Hospital Respiratory Physicians therefore promoted a prospective multicenter epidemiological study: the ESCAP study. This study was aimed to describe the therapeutic strategies implemented during the first 2-year after diagnosis in patients with LC followed in French General Hospital chest departments. We report below descriptive results for metastatic non-small-cell lung cancer (mNSCLC).
Methods:
For each patient with a LC diagnosed in 2010, a standardized form was completed at diagnosis and following each change in treatment strategy up to at least 2 years after diagnosis.
Results:
53 centers participated in the ESCAP study and included 3,943 patients. Among them, 3,418 patients had a NSCLC. NSCLC was metastatic in 2,003 patients. In patients with mNSCLC, the first therapeutic strategy was chemotherapy alone (56%) followed by palliative chemotherapy plus incidental radiotherapy (35%); 4% of patients died without any implemented therapeutic strategy (see figure). 29% of patients with chemotherapy alone as first strategy died without undergoing any other strategy and 70% had a second strategy (72% chemotherapy alone). 35% of patients with radiochemotherapy died without undergoing any other strategy and 64% had a 2[nd] strategy (73% chemotherapy alone). Figure 1 The most frequent chemotherapy during the first strategy was platinum salts doublet with pemetrexed (39%), followed by platinum salts doublet with paclitaxel (15%). Chemotherapy during the second strategy was second line chemotherapy (67%) or maintenance therapy (25%). EGFR-TKi (34%) and docetaxel (26%) alone were the most frequently prescribed drugs for second line chemotherapy, and pemetrexed (44%) and EGFR-TKi (26%) alone for maintenance therapy.
Conclusion:
The ESCAP study describes the 2-year management of metastatic NSCLC on real-life settings in France. Its preliminary results are consistent with the guidelines of the French National Cancer Institute.
